← Back to search
RAFA LABORATORIES LTD
JERUSALEM
UnclaimedClaim this profile (free)
Prime contracting experience
3 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE FOLLOWING DEVELOPMENT ESSENTIALS: CMC DEVELOPMENT, PRE-CLINICAL AND CLINICAL STUDIES, DEVICE DEVELOPMENT ACTIVITIES, HUMAN FACTORS TESTING, MARKET VIABILITY ASSESSMENTS ALONG WITH ALL ASSOCIATED REGULA | — | $11,997,762 | Aug 10, 2026 | Sep 29, 2025 – Dec 31, 2028 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | RAFA ATROPINE AUTO-INJECTORS (0.5 MG, 1 MG, AND 2 MG) | — | $33,392,937 | Jul 29, 2026 | Sep 30, 2025 – Sep 29, 2027 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT, INCLUDING U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL, OF ATROPINE AUTOINJECTOR FOR PEDIATRIC USE USING AN IMPROVED VERSION OF RAFA LABORATORIES, LTD.S (RAFAS) FDA-APPROVED SI | — | $9,371,145 | Sep 22, 2025 | Sep 19, 2023 – Aug 4, 2028 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.